EVI2B May be a Novel Prognostic Marker for Lung Adenocarcinoma

Objective: This study intended to unravel the relationship of EVI2B expression with lung adenocarcinoma (LUAD). Methods: TIMER1.0, Gene Expression Profiling Interactive Analysis and Human Protein Atlas databases, as well as the University of Alabama at Birmingham Cancer website, were used to analyze the expression of EVI2B and its relationship with clinical features. The relationship between survival curve analysis and prognosis was analyzed. The role of EVI2B in LUAD was verified by wet experiments. Results:EVI2B was markedly downregulated in LUAD. There was a relationship between the expression of EVI2B and clinical features. Low EVI2B level was substantially implicated in low survival in LUAD. EVI2B overexpression constrained LUAD cell viability, migration and invasion. Conclusion:EVI2B was related to prognosis and immune microenvironment in LUAD, suggesting that EVI2B may be a novel prognostic marker for LUAD.Lung adenocarcinoma (LUAD) is a type of cancer. It causes many deaths. However, there is no good treatment for it yet. Scientists found a gene called EVI2B. EVI2B can help show how bad the cancer is. EVI2B is at a low level in LUAD. When it is high, patients have a better chance of surviving. EVI2B is linked to the immune system fighting cancer. It can be used to check the progression of LUAD. EVI2B may help with new treatments in the future.